Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from Dis-CoVeRy and the EU-SolidAct EU response group.

Diallo, A; Troseid, M; Simensen, VC; Boston, A; Demotes, J; Olsen, IC; Chung, F; Paiva, JA; Hites, M; Ader, F; Arribas, JR; Baratt-Due, A; Melien, O; Tacconelli, E; Staub, T; Greil, R; Tsiodras, S; Briel, M; Esperou, H; Mentre, F; Eustace, J; Saillard, J; Delmas, C; LeMestre, S; Dumousseaux, M; Costaglio-la, D; Rottingen, JA; Yazdanpanah, Y. Clin Microbiol Infect. 2022 Jan;28(1):1-5. doi: 10.1016/j.cmi.2021.10.011. E-pub 2021 Nov 8.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).

Gnant, M; Dueck, AC; Frantal, S; Martin, M; Burstein, HJ; Greil, R; Fox, P; Wolff, AC; Chan, A; Winer, EP; Pfeiler, G; Miller, KD; Colleoni, M; Suga, JM; Rubovsky, G; Bliss, JM; Mayer, IA; Singer, CF; Nowecki, Z; Hahn, O; Thom-son, J; Wolmark, N; Amillano, K; Rugo, HS; Steger, GG; Hernando Fernández de Aránguiz, B; Haddad, TC; Perelló, A; Bellet, M; Fohler, H; Metzger Filho, O; Jallitsch-Halper, A; Solomon, K; Schurmans, C; Theall, KP; Lu, DR; Tenner, K; Fesl, C; DeMichele, A; Mayer, EL. J Clin Oncol. 2022 Jan 20;40(3):282-293. doi: 10.1200/JCO.21.02554. Epub 2021 Dec 7.

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.

Kuemmel, S; Campone, M; Loirat, D; Lopez, RL; Beck, JT; De Laurentiis, M; Im, SA; Kim, SB; Kwong, A; Steger, GG; Adelantado, EZ; Duhoux, FP; Greil, R; Kuter, I; Lu, YS; Tibau, A; Özgüroğlu, M; Scholz, CW; Singer, CF; Vega, E; Wimberger, P; Zamagni, C; Couillebault, XM; Fan, L; Guerreiro, N; Mataraza, J; Sand-Dejmek, J; Chan, A. Clin Cancer Res. 2022 Jan 1;28(1):106-115. doi: 10.1158/1078-0432.CCR-20-3955. Epub 2021 Oct 6.

Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.

Schlintl, V; Huemer, F; Rinnerthaler, G; Melchardt, T; Winder, T; Reimann, P; Riedl, J; Amann, A; Eisterer, W; Romeder, F; Piringer, G; Ilhan-Mutlu, A; Wöll, E; Greil, R; Weiss, L. BMC Cancer. 2022 Jan 10;22(1):51. doi: 10.1186/s12885-021-09115-6.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lym-phoma.

Tilly, H; Morschhauser, F; Sehn, LH; Friedberg, JW; Trneny, M; Sharman, JP; Herbaux, C; Burke, JM; Matasar, M; Rai, S; Izutsu, K; Mehta-Shah, N; Oberic, L; Chauchet, A; Jurczak, W; Song, YQ; Greil, R; Mykhalska, L; Bergua-Burgues, JM; Cheung, MC; Pinto, A; Shin, HJ; Hapgood, G; Munhoz, E; Ab-risqueta, P; Gau, JP; Hirata, J; Jiang, YW; Yan, M; Lee, C; Flowers, CR; Sal-les, G. N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.

Evaluating a Targeted Cancer Therapy Approach Mediated by RNA.

Woess, K; Sun, Y; Morio, H; Stierschneider, A; Kaufmann, A; Hainzl, S; Tratt-ner, L; Kocher, T; Tockner, B; Leb-Reichl, V; Steiner, M; Brachtl, G; South, AP; Bauer, JW; Reichelt, J; Furihata, T; Wally, V; Koller, U; Piñón Hofbauer, J; Guttmann-Gruber, C. Int J Mol Sci. 2022 Jan 5;23(1):575. doi: 10.3390/ijms23010575.

Kindlin-3 maintains marginal zone B cells but confines follicular B cell activation and differentiation.

Härzschel A, Li L, Krenn PW, Szenes-Nagy E, Andrieux G, Bayer E, Pfei-fer D, Polcik L, Denk U, Höpner JP, Karabatak E, Danner DJ, Tangermann S, Kenner L, Jumaa H, Greil R, Börries M, Ruppert R, Maity PC, Hartmann TN. J Leukoc Biol. 2021 Dec 10. doi: 10.1002/JLB.1HI0621-313R. Online ahead of print. PMID: 34888947

Challenges in measuring phosphoproteomics with CyTOF in CLL.

Markus Steiner, Daniela Asslaber, Nadja Zaborsky, Alexander Egle, Richard Greil. 5th German Mass Cytometry User Forum; 20.01.-21.01.2022; Online.

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.

Gampenrieder, SP; Rinnerthaler, G; Tinchon, C; Petzer, A; Balic, M; Heibl, S; Schmitt, C; Zabernigg, AF; Egle, D; Sandholzer, M; Singer, CF; Roitner, F; Hager, C; Andel, J; Hubalek, M; Knauer, M; Greil, R. Breast Cancer Res. 2021 Dec 14;23(1):112. doi: 10.1186/s13058-021-01492-x.

Persistence of ctDNA in breast cancer patients during neoadjuvant treatment is a significant predictor of poor tumour response.

Zhou, Q; Gampenrieder, SP; Frantal, S; Rinnerthaler, G; Singer, CF; Egle, D; Pfeiler, G; Bartsch, R; Wette, V; Pichler, A; Petru, E; Dubsky, PC; Bago-Horvath, Z; Fesl, C; Rudas, M; Ståhlberg, A; Graf, R; Weber, S; Dandachi, N; Filipits, M; Gnant, M; Balic, M; Heitzer, E. Clin Cancer Res. 2021 Dec 3. doi: 10.1158/1078-0432.CCR-21-3231. On-line ahead of print.